Management of Hyperlipidemia in a Clinical Pathway Unit

Disease Management

Volumn 1, Issue 3, 1998, Pages 111-120

  Freeman, Dale A ^a   Britton, Mark L ^b   Letassy, Nancy A ^b   Beck, Joni ^b   Sirmans, Susan ^b   Neal, Araceli ^c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c Affairs Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000625514     PISSN: 1093507X     EISSN: None     Source Type: Journal    
DOI: 10.1089/dis.1998.1.111     Document Type: Article

References (18)

1. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977.
2. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trials results in reduction in the incidence of coronary heart disease. JAMA 1984;251:351.
3. Canner P. L., Berge K. G., Wenger N. K., et al. Fifteen year mortality in coronary drug project patients: Long term benefit with niacin. J Am Col Cardiol 1986;8:1245.
4. Blankenhorn D. H., Nessim S. A., Johnson R. L., et al: Beneficial effects of combined colestipol-niacin therapy on coronary artery atherosclerosis and coronary venous bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. JAMA 1987;257:3233.
5. Buckwald H., Vareo R. I., Matts I. P., et al. Effect of partial ilial bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med 1990;323:945.
6. Brown G., Albers J. J., Fisher L. D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289.
7. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383.
8. Superko H. R., Krauss R. M.: Coronary artery disease regression: Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994; 90:1056.
9. Shepherd J., Cobbe S. M., Ford I., et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;33:1301.
10. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988;148:36.
11. National Institutes of Health. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015.
12. Richlie D. B., Winters S., Prochazka A. V. Dyslipidemia in veterans. Arch Intern Med 1991;151:1433.
13. Frick M. H., Heinoven O. P., Huffman I. K., et al. Efficacy of Gemfibrozil in dyslipidaemic subjects with suspected heart disease. Ann Med 1993;25:41.
14. Wittels E. H., Hay I. W., Gotto A. M. Medical costs of coronary artery disease in the United States. AM J Cardiol 1990;65:432–440.
15. Hay J. W., Wittels E. H., Gotto A. M. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol 1991;67:789.
16. Schectman G., Wolff N., Byrd J. C., et al. Physician extenders for cost effective management of hypercholesterolemia. J Gen Intern Med 1996;11:277.
17. Debusk R., Miller N., Superko H., et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 1994;120:721.
18. Shaffer J., Wexler L. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Arch Intern Med 1995;155:2330.